SML2915

SAR-20347

≥98% (HPLC)

• Sinónimos: 2-(2-Chloro-6-fluorophenyl)-5-(4-(morpholine-4-carbonyl)phenylamino)oxazole-4-carboxamide, 2-(2-Chloro-6-fluorophenyl)-5-[[4-(4-morpholinylcarbonyl)phenyl]amino]-4-oxazolecarboxamide, SAR 20347, SAR20347
• Fórmula empírica (notación de Hill): C₂₁H₁₈ClFN₄O₄
• Número CAS: 1450881-55-6
• Peso molecular: 444.84
• UNSPSC Code: 12352200
• NACRES: NA.77
• MDL number: MFCD28502117
• Assay: ≥98% (HPLC)
• Form: powder

Propiedades

• Quality Segment: 100
• assay: ≥98% (HPLC)
• form: powder
• color: white to beige
• solubility: DMSO: 2 mg/mL, clear
• storage temp.: −20°C
• SMILES string: Fc1c(c(ccc1)Cl)c2nc(c([o]2)Nc3ccc(cc3)C(=O)N4CCOCC4)C(=O)N
• InChI: 1S/C21H18ClFN4O4/c22-14-2-1-3-15(23)16(14)19-26-17(18(24)28)20(31-19)25-13-6-4-12(5-7-13)21(29)27-8-10-30-11-9-27/h1-7,25H,8-11H2,(H2,24,28)
• InChI key: HEDPDFHTQKEORT-UHFFFAOYSA-N

Descripción

Biochem/physiol Actions

Orally active, ATP-competitive, TYK2- and JAK1-selective tyrosine kinase inhibitor in vitro and in vivo.

SAR-20347 is an orally active, ATP-competitive, TYK2- and JAK1-selective tyrosine kinase inhibitor (IC₅₀ = 13 nM/TYK2 & 59 nM/JAK1 vs. 0.88 μM/JAK2 & 1.44 μM/JAK3 with 10 μM ATP) that effectively inhibits cellular TYK2- (IL12-induced pSTAT4 IC₅₀ = 107 nM/CD4+ cells, 126 nM/NK-92) and JAK1- (IL6-induced pSTAT3 IC₅₀ = 345 nM/TF-1, 407 nM/CD14+ cells) mediated signaling with little affinity toward 72 other kinases. SAR-20347 suppresses IL22-induced serum amyloid A (by 44%; 50 mg/kg p.o. 30 min prior to 10 μg IL22 i.p.) and alleviates imiquimod-induced psoriasis-like dermatitis (30 min prior and 5 h post daily 62.5 mg 5% imiquimod cream) in mice in vivo.

Información de seguridad

• Clase de almacenamiento: 11 - Combustible Solids
• ¿Qué está pasando?: WGK 3